Biogen Idec Partners with Isis Pharmaceuticals in $100M Drug Deal

Biogen will pay Isis $100 million upfront and up to $220 million per compound in potential milestone payments
Sept. 10, 2013

Biogen Idec Inc., maker of the multiple sclerosis pill Tecfidera, expanded its partnership with Isis Pharmaceuticals Inc. in a deal to develop drugs for neurological disorders. Read the full story

Sign up for our eNewsletters
Get the latest news and updates

Related

Fujifilm Biotechnologies to leverage downstream purification system at UK site
Fujifilm’s modular, scalable manufacturing takes shape amid complex global supply chain
2026 Manufacturing Pharma Trends for Life Sciences
Sponsored
2026 AI Trends in Life Sciences
Sponsored